Newsbenzinga
Artiva Biotherapeutics Plunges Into Crisis Over Patient Deaths and Possible Liquidation
· Published
Article summary
Artiva Biotherapeutics ends its AlloNK program after fatal safety events, slashes 94% of its workforce, and weighs strategic liquidation.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…